Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724411 | 0.90 | MAPT (0.42) | MAPTCHEK1JAK2ALKMAP3K11 | |
| SCHEMBL676473 | 0.87 | MAPT (0.40) | SYKMAPTCHEK1JAK2ALK | |
| SCHEMBL676452 | 0.85 | CHEK1 (0.47) | SYKMAPTKDRCHEK1ZAP70 | |
| SCHEMBL676454 | 0.84 | MAPT (0.41) | SYKMAPTCHEK1JAK2ALK | |
| SCHEMBL674333 | 0.83 | MAPT (0.53) | SYKMAPTCHEK1JAK2ALK | |
| SCHEMBL676471 | 0.83 | ALK (0.45) | SYKMAPTKDRCHEK1JAK2 | |
| SCHEMBL676886 | 0.81 | MAPT (0.40) | MAPTCHEK1JAK2ALKMAP3K11 | |
| SCHEMBL3666284 | 0.81 | MAPT (0.48) | MAPTCHEK1JAK2ALKMAP3K11 | |
| SCHEMBL676472 | 0.80 | ALK (0.41) | MAPTCHEK1ZAP70JAK2ALK | |
| SCHEMBL675875 | 0.79 | JAK2 (0.52) | CHEK1JAK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | SYK 42/4885MAPT 1494/4885KDR 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.